The company develops, produces, and markets hybrid seeds for crops like cotton, paddy, maize, and vegetables, alongside plant nutrition supplements for Indian and international farmers.
The company possesses a narrow moat based on its proprietary germplasm and DSIR-recognized R&D centers, which create high-yielding, disease-resistant hybrids. However, the moat is weakened by low average ROCE (8.1%) and the proliferation of illegal unorganized seeds in the cotton segment.
Management prioritizes reinvestment into R&D and working capital for inventory build-up, with a conservative approach to fixed assets by utilizing leased processing facilities. While they maintain a low debt-to-equity ratio, the historical returns on equity (7.1%) suggest reinvested capital is not yet generating high incremental value.
The investment collapsed as the company's massive inventory and trade receivables proved to be uncollectible or obsolete, leading to a liquidity crisis. Despite the R&D efforts, the proliferation of illegal, unorganized seeds eroded the cotton segment's market share, while the capital tied up in working capital failed to generate returns above the cost of capital. The low cash conversion finally caught up with the business, forcing a massive write-down of assets and a dilution of equity to cover operating shortfalls.
RichFakir rates Nath Bio-Genes (India) Ltd's business quality as mediocre — 47/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Nath Bio-Genes (India) Ltd is trading about 66% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Nath Bio-Genes (India) Ltd is: Not rated. Mediocre business (score 47), but the valuation is low-confidence, so we are not calling it a bargain.
RichFakir's educational estimate of Nath Bio-Genes (India) Ltd's fair value is about ₹387 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →